



Affymetrix Inc.

Media Contact:

Andrew Noble
Sr. Manager, Corporate Communications
408-731-5571

Investor Contact:

Doug Farrell
Vice President, Investor Relations
408-731-5285

NEWS RELEASE

AFFYMETRIX SELECTS SINGAPORE FOR ITS FIRST MANUFACTURING FACILITY OUTSIDE THE UNITED STATES

SINGAPORE, May 23, 2007 – Affymetrix Inc. (NASDAQ:AFFX), a pioneer in creating breakthrough tools that are driving the genomic revolution, today officially opened its manufacturing facility in Singapore. The new state-of-the-art building is Affymetrix's first manufacturing facility outside of the United States of America, enabling the company to better serve and support its growing international business.

Affymetrix develops and commercializes microarray systems that enable scientists to improve quality of life. Its GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostics and biotechnology companies, as well as leading academic, government and not-for-profit research institutes, to analyze the relationship between genes and human health. More than 1,500 systems have been shipped around the world and more than 8,500 peer-reviewed papers have been published using the technology.

After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a

more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.

“While Singapore offers a number of significant economic, political and lifestyle advantages, Affymetrix was most impressed with the country’s commitment and support to the life sciences industry. In fact, a number of our most innovative and highly valued customers are here in Singapore, doing research in everything from cancer to population genetics to diabetes,” said Mr Kevin King, president of life sciences business and executive vice president, Affymetrix. “This new facility enables us to better serve and support our growing customer base around the world.”

“This is an exciting day for Affymetrix as we officially open this state-of-the-art manufacturing facility,” said Mr Warren Kocmond, senior vice president of global operations at Affymetrix. “Singapore is well-known for its highly educated, highly motivated work force and the local team did a tremendous job getting the site up and running in record time. We are proud to welcome these new colleagues to the Affymetrix family.”

The opening ceremony was officiated by Ms Aw Kah Peng, Assistant Managing Director, Economic Development Board. She said: “We are very pleased that Affymetrix is officially opening its manufacturing facility here. Within a short span of two years, five Scientific Instrumentation companies, including Affymetrix, have decided to set up manufacturing operations in Singapore. Singapore’s strong process R&D capabilities in electronics and precision engineering, large pool of well-educated workers, and competitive tax environment are some of the reasons why companies like Affymetrix are attracted to manufacture high value products in Singapore.”

The Singapore facility is located at the Keppel Logistics Building at Gul Circle, Jurong Industrial Park. It has been operational since the end of 2006 and employs 120 staff members. It was designed to look and operate like Affymetrix’s main manufacturing facility in West Sacramento. By the end of 2007, Affymetrix plans to shift approximately 40 percent of its total microarray production to Singapore.

About Affymetrix

Affymetrix is headquartered in Santa Clara, Calif. and has manufacturing facilities in West Sacramento, Calif. and Singapore. The company has about 1,100 employees worldwide and maintains sales and marketing operations in Europe and Asia. For more information about Affymetrix, please visit the company's website at www.affymetrix.com.

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix's "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the success of the Singapore manufacturing facility discussed in this press release; risks of the company's ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole source suppliers; uncertainties related to FDA and other regulatory approvals; competition; risks related to the intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix's Form 10-K for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.

###

Issued on behalf of:	Affymetrix Pte Ltd
By:	Foreword Communications Pte Ltd
Contact:	Ms Cecilia Tan or Ms Juliana Teo
Telephone:	(+65) 6338-5918
Email:	cecilia@foreword.com.sg or juliana@foreword.com.sg
